nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2C—type 2 diabetes mellitus	0.199	0.667	CbGaD
Atomoxetine—CYP3A4—type 2 diabetes mellitus	0.0993	0.333	CbGaD
Atomoxetine—HTR6—Bromocriptine—type 2 diabetes mellitus	0.0512	0.119	CbGbCtD
Atomoxetine—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0467	0.109	CbGbCtD
Atomoxetine—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0448	0.104	CbGbCtD
Atomoxetine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0298	0.0693	CbGbCtD
Atomoxetine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0268	0.0625	CbGbCtD
Atomoxetine—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0201	0.0468	CbGbCtD
Atomoxetine—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0171	0.0398	CbGbCtD
Atomoxetine—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0171	0.0398	CbGbCtD
Atomoxetine—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.0158	0.0367	CbGbCtD
Atomoxetine—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0152	0.0354	CbGbCtD
Atomoxetine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.013	0.0302	CbGbCtD
Atomoxetine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0128	0.0298	CbGbCtD
Atomoxetine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.012	0.0279	CbGbCtD
Atomoxetine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0114	0.0266	CbGbCtD
Atomoxetine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0105	0.0243	CbGbCtD
Atomoxetine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00985	0.0229	CbGbCtD
Atomoxetine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00944	0.022	CbGbCtD
Atomoxetine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00914	0.0213	CbGbCtD
Atomoxetine—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00875	0.0204	CbGbCtD
Atomoxetine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00826	0.0192	CbGbCtD
Atomoxetine—CYP2C19—Losartan—type 2 diabetes mellitus	0.008	0.0186	CbGbCtD
Atomoxetine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00626	0.0146	CbGbCtD
Atomoxetine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.006	0.014	CbGbCtD
Atomoxetine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.006	0.014	CbGbCtD
Atomoxetine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00568	0.0132	CbGbCtD
Atomoxetine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00423	0.00984	CbGbCtD
Atomoxetine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00387	0.009	CbGbCtD
Atomoxetine—NPY1R—nerve—type 2 diabetes mellitus	0.00366	0.109	CbGeAlD
Atomoxetine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00329	0.0974	CbGeAlD
Atomoxetine—HTR2A—arteriole—type 2 diabetes mellitus	0.0031	0.0919	CbGeAlD
Atomoxetine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00221	0.0655	CbGeAlD
Atomoxetine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00197	0.0586	CbGeAlD
Atomoxetine—HTR1B—artery—type 2 diabetes mellitus	0.00157	0.0464	CbGeAlD
Atomoxetine—SLC6A3—nerve—type 2 diabetes mellitus	0.00154	0.0457	CbGeAlD
Atomoxetine—HTR1D—artery—type 2 diabetes mellitus	0.00152	0.0449	CbGeAlD
Atomoxetine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.00133	0.0394	CbGeAlD
Atomoxetine—NPY1R—pancreas—type 2 diabetes mellitus	0.00125	0.0369	CbGeAlD
Atomoxetine—SLC6A2—nerve—type 2 diabetes mellitus	0.00124	0.0368	CbGeAlD
Atomoxetine—HTR2A—hindlimb—type 2 diabetes mellitus	0.00123	0.0364	CbGeAlD
Atomoxetine—NPY1R—cortex of kidney—type 2 diabetes mellitus	0.00122	0.0362	CbGeAlD
Atomoxetine—NPY1R—adipose tissue—type 2 diabetes mellitus	0.00113	0.0335	CbGeAlD
Atomoxetine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000958	0.0284	CbGeAlD
Atomoxetine—NPY1R—liver—type 2 diabetes mellitus	0.000793	0.0235	CbGeAlD
Atomoxetine—HTR2A—artery—type 2 diabetes mellitus	0.000753	0.0223	CbGeAlD
Atomoxetine—HTR2A—nerve—type 2 diabetes mellitus	0.000747	0.0221	CbGeAlD
Atomoxetine—HTR2A—endothelium—type 2 diabetes mellitus	0.000636	0.0189	CbGeAlD
Atomoxetine—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000544	0.0161	CbGeAlD
Atomoxetine—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000527	0.0156	CbGeAlD
Atomoxetine—HTR1D—kidney—type 2 diabetes mellitus	0.000515	0.0153	CbGeAlD
Atomoxetine—HTR2A—retina—type 2 diabetes mellitus	0.000309	0.00917	CbGeAlD
Atomoxetine—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000262	0.00776	CbGeAlD
Atomoxetine—HTR2A—kidney—type 2 diabetes mellitus	0.000256	0.00759	CbGeAlD
Atomoxetine—CYP2C19—liver—type 2 diabetes mellitus	0.000253	0.00751	CbGeAlD
Atomoxetine—CYP3A4—kidney—type 2 diabetes mellitus	0.000237	0.00703	CbGeAlD
Atomoxetine—CYP2D6—kidney—type 2 diabetes mellitus	0.000233	0.00691	CbGeAlD
Atomoxetine—Reboxetine—HTR2C—type 2 diabetes mellitus	0.000199	0.0564	CrCbGaD
Atomoxetine—Phenoxybenzamine—CALM1—type 2 diabetes mellitus	0.000185	0.0525	CrCbGaD
Atomoxetine—Propranolol—ADRB3—type 2 diabetes mellitus	0.000182	0.0518	CrCbGaD
Atomoxetine—HTR2A—liver—type 2 diabetes mellitus	0.000162	0.0048	CbGeAlD
Atomoxetine—Duloxetine—HTR2C—type 2 diabetes mellitus	0.000153	0.0434	CrCbGaD
Atomoxetine—CYP3A4—liver—type 2 diabetes mellitus	0.00015	0.00444	CbGeAlD
Atomoxetine—CYP2D6—liver—type 2 diabetes mellitus	0.000147	0.00437	CbGeAlD
Atomoxetine—Fluoxetine—HTR2C—type 2 diabetes mellitus	0.000125	0.0354	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRA2A—type 2 diabetes mellitus	0.000118	0.0334	CrCbGaD
Atomoxetine—Maprotiline—HTR2C—type 2 diabetes mellitus	0.000116	0.033	CrCbGaD
Atomoxetine—Duloxetine—CYP1A2—type 2 diabetes mellitus	0.000115	0.0327	CrCbGaD
Atomoxetine—Pseudoephedrine—TNF—type 2 diabetes mellitus	0.000111	0.0316	CrCbGaD
Atomoxetine—Reboxetine—CYP3A4—type 2 diabetes mellitus	9.93e-05	0.0282	CrCbGaD
Atomoxetine—Myalgia—Metformin—type 2 diabetes mellitus	9.84e-05	0.000655	CcSEcCtD
Atomoxetine—Vertigo—Irbesartan—type 2 diabetes mellitus	9.8e-05	0.000653	CcSEcCtD
Atomoxetine—Headache—Pioglitazone—type 2 diabetes mellitus	9.79e-05	0.000652	CcSEcCtD
Atomoxetine—Syncope—Irbesartan—type 2 diabetes mellitus	9.78e-05	0.000652	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	9.77e-05	0.000651	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	9.73e-05	0.000648	CcSEcCtD
Atomoxetine—Fatigue—Gliclazide—type 2 diabetes mellitus	9.72e-05	0.000648	CcSEcCtD
Atomoxetine—Nausea—Glipizide—type 2 diabetes mellitus	9.69e-05	0.000646	CcSEcCtD
Atomoxetine—Vomiting—Glimepiride—type 2 diabetes mellitus	9.68e-05	0.000645	CcSEcCtD
Atomoxetine—Vision blurred—Losartan—type 2 diabetes mellitus	9.67e-05	0.000644	CcSEcCtD
Atomoxetine—Vomiting—Sitagliptin—type 2 diabetes mellitus	9.65e-05	0.000643	CcSEcCtD
Atomoxetine—Pain—Gliclazide—type 2 diabetes mellitus	9.64e-05	0.000642	CcSEcCtD
Atomoxetine—Constipation—Gliclazide—type 2 diabetes mellitus	9.64e-05	0.000642	CcSEcCtD
Atomoxetine—Tremor—Losartan—type 2 diabetes mellitus	9.62e-05	0.000641	CcSEcCtD
Atomoxetine—Rash—Glimepiride—type 2 diabetes mellitus	9.6e-05	0.000639	CcSEcCtD
Atomoxetine—Dermatitis—Glimepiride—type 2 diabetes mellitus	9.59e-05	0.000639	CcSEcCtD
Atomoxetine—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	9.59e-05	0.000639	CcSEcCtD
Atomoxetine—Rash—Sitagliptin—type 2 diabetes mellitus	9.57e-05	0.000637	CcSEcCtD
Atomoxetine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	9.56e-05	0.000637	CcSEcCtD
Atomoxetine—Headache—Glimepiride—type 2 diabetes mellitus	9.54e-05	0.000635	CcSEcCtD
Atomoxetine—Cough—Irbesartan—type 2 diabetes mellitus	9.52e-05	0.000634	CcSEcCtD
Atomoxetine—Headache—Sitagliptin—type 2 diabetes mellitus	9.51e-05	0.000633	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	9.44e-05	0.000629	CcSEcCtD
Atomoxetine—Agitation—Losartan—type 2 diabetes mellitus	9.43e-05	0.000628	CcSEcCtD
Atomoxetine—Fluoxetine—CYP1A2—type 2 diabetes mellitus	9.4e-05	0.0267	CrCbGaD
Atomoxetine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	9.4e-05	0.000626	CcSEcCtD
Atomoxetine—Flushing—Ramipril—type 2 diabetes mellitus	9.38e-05	0.000625	CcSEcCtD
Atomoxetine—Infection—Metformin—type 2 diabetes mellitus	9.37e-05	0.000624	CcSEcCtD
Atomoxetine—Insomnia—Valsartan—type 2 diabetes mellitus	9.37e-05	0.000624	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	9.33e-05	0.000621	CcSEcCtD
Atomoxetine—Paraesthesia—Valsartan—type 2 diabetes mellitus	9.3e-05	0.00062	CcSEcCtD
Atomoxetine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	9.29e-05	0.000619	CcSEcCtD
Atomoxetine—Arthralgia—Irbesartan—type 2 diabetes mellitus	9.29e-05	0.000619	CcSEcCtD
Atomoxetine—Chest pain—Irbesartan—type 2 diabetes mellitus	9.29e-05	0.000619	CcSEcCtD
Atomoxetine—Myalgia—Irbesartan—type 2 diabetes mellitus	9.29e-05	0.000619	CcSEcCtD
Atomoxetine—Shock—Metformin—type 2 diabetes mellitus	9.28e-05	0.000618	CcSEcCtD
Atomoxetine—Insomnia—Orlistat—type 2 diabetes mellitus	9.26e-05	0.000617	CcSEcCtD
Atomoxetine—Anxiety—Irbesartan—type 2 diabetes mellitus	9.25e-05	0.000616	CcSEcCtD
Atomoxetine—Nervous system disorder—Metformin—type 2 diabetes mellitus	9.25e-05	0.000616	CcSEcCtD
Atomoxetine—Vertigo—Losartan—type 2 diabetes mellitus	9.22e-05	0.000614	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	9.22e-05	0.000614	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	9.22e-05	0.000614	CcSEcCtD
Atomoxetine—Somnolence—Valsartan—type 2 diabetes mellitus	9.21e-05	0.000613	CcSEcCtD
Atomoxetine—Syncope—Losartan—type 2 diabetes mellitus	9.21e-05	0.000613	CcSEcCtD
Atomoxetine—Paraesthesia—Orlistat—type 2 diabetes mellitus	9.19e-05	0.000612	CcSEcCtD
Atomoxetine—Skin disorder—Metformin—type 2 diabetes mellitus	9.16e-05	0.00061	CcSEcCtD
Atomoxetine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	9.12e-05	0.000607	CcSEcCtD
Atomoxetine—Dyspepsia—Valsartan—type 2 diabetes mellitus	9.12e-05	0.000607	CcSEcCtD
Atomoxetine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	9.11e-05	0.000607	CcSEcCtD
Atomoxetine—Dizziness—Bromocriptine—type 2 diabetes mellitus	9.08e-05	0.000605	CcSEcCtD
Atomoxetine—Dry mouth—Irbesartan—type 2 diabetes mellitus	9.08e-05	0.000605	CcSEcCtD
Atomoxetine—Palpitations—Losartan—type 2 diabetes mellitus	9.07e-05	0.000604	CcSEcCtD
Atomoxetine—Nausea—Glimepiride—type 2 diabetes mellitus	9.04e-05	0.000602	CcSEcCtD
Atomoxetine—Loss of consciousness—Losartan—type 2 diabetes mellitus	9.02e-05	0.000601	CcSEcCtD
Atomoxetine—Nausea—Sitagliptin—type 2 diabetes mellitus	9.02e-05	0.000601	CcSEcCtD
Atomoxetine—Dyspepsia—Orlistat—type 2 diabetes mellitus	9.01e-05	0.0006	CcSEcCtD
Atomoxetine—Asthenia—Glyburide—type 2 diabetes mellitus	9.01e-05	0.0006	CcSEcCtD
Atomoxetine—Decreased appetite—Valsartan—type 2 diabetes mellitus	9.01e-05	0.0006	CcSEcCtD
Atomoxetine—Anorexia—Metformin—type 2 diabetes mellitus	8.99e-05	0.000599	CcSEcCtD
Atomoxetine—Cough—Losartan—type 2 diabetes mellitus	8.96e-05	0.000597	CcSEcCtD
Atomoxetine—Urticaria—Gliclazide—type 2 diabetes mellitus	8.96e-05	0.000597	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	8.94e-05	0.000596	CcSEcCtD
Atomoxetine—Fatigue—Valsartan—type 2 diabetes mellitus	8.93e-05	0.000595	CcSEcCtD
Atomoxetine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	8.91e-05	0.000594	CcSEcCtD
Atomoxetine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	8.91e-05	0.000594	CcSEcCtD
Atomoxetine—Decreased appetite—Orlistat—type 2 diabetes mellitus	8.9e-05	0.000593	CcSEcCtD
Atomoxetine—Pruritus—Glyburide—type 2 diabetes mellitus	8.88e-05	0.000592	CcSEcCtD
Atomoxetine—Mental disorder—Ramipril—type 2 diabetes mellitus	8.86e-05	0.00059	CcSEcCtD
Atomoxetine—Constipation—Valsartan—type 2 diabetes mellitus	8.86e-05	0.00059	CcSEcCtD
Atomoxetine—Infection—Irbesartan—type 2 diabetes mellitus	8.84e-05	0.000589	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	8.84e-05	0.000589	CcSEcCtD
Atomoxetine—Fatigue—Orlistat—type 2 diabetes mellitus	8.83e-05	0.000588	CcSEcCtD
Atomoxetine—Malnutrition—Ramipril—type 2 diabetes mellitus	8.8e-05	0.000586	CcSEcCtD
Atomoxetine—Maprotiline—CYP1A2—type 2 diabetes mellitus	8.78e-05	0.0249	CrCbGaD
Atomoxetine—Benzphetamine—ADRA2A—type 2 diabetes mellitus	8.77e-05	0.0249	CrCbGaD
Atomoxetine—Shock—Irbesartan—type 2 diabetes mellitus	8.76e-05	0.000583	CcSEcCtD
Atomoxetine—Pain—Orlistat—type 2 diabetes mellitus	8.75e-05	0.000583	CcSEcCtD
Atomoxetine—Arthralgia—Losartan—type 2 diabetes mellitus	8.74e-05	0.000582	CcSEcCtD
Atomoxetine—Myalgia—Losartan—type 2 diabetes mellitus	8.74e-05	0.000582	CcSEcCtD
Atomoxetine—Chest pain—Losartan—type 2 diabetes mellitus	8.74e-05	0.000582	CcSEcCtD
Atomoxetine—Vomiting—Bromocriptine—type 2 diabetes mellitus	8.73e-05	0.000582	CcSEcCtD
Atomoxetine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	8.73e-05	0.000582	CcSEcCtD
Atomoxetine—Anxiety—Losartan—type 2 diabetes mellitus	8.71e-05	0.00058	CcSEcCtD
Atomoxetine—Tachycardia—Irbesartan—type 2 diabetes mellitus	8.69e-05	0.000579	CcSEcCtD
Atomoxetine—Rash—Bromocriptine—type 2 diabetes mellitus	8.66e-05	0.000577	CcSEcCtD
Atomoxetine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	8.65e-05	0.000576	CcSEcCtD
Atomoxetine—Skin disorder—Irbesartan—type 2 diabetes mellitus	8.65e-05	0.000576	CcSEcCtD
Atomoxetine—Tension—Ramipril—type 2 diabetes mellitus	8.64e-05	0.000575	CcSEcCtD
Atomoxetine—Dysgeusia—Ramipril—type 2 diabetes mellitus	8.62e-05	0.000574	CcSEcCtD
Atomoxetine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	8.61e-05	0.000573	CcSEcCtD
Atomoxetine—Headache—Bromocriptine—type 2 diabetes mellitus	8.6e-05	0.000573	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	8.59e-05	0.000572	CcSEcCtD
Atomoxetine—Diarrhoea—Glyburide—type 2 diabetes mellitus	8.59e-05	0.000572	CcSEcCtD
Atomoxetine—Warfarin—CYP1A2—type 2 diabetes mellitus	8.57e-05	0.0243	CrCbGaD
Atomoxetine—Nervousness—Ramipril—type 2 diabetes mellitus	8.55e-05	0.000569	CcSEcCtD
Atomoxetine—Dry mouth—Losartan—type 2 diabetes mellitus	8.55e-05	0.000569	CcSEcCtD
Atomoxetine—Anorexia—Irbesartan—type 2 diabetes mellitus	8.49e-05	0.000565	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	8.47e-05	0.000564	CcSEcCtD
Atomoxetine—Paraesthesia—Metformin—type 2 diabetes mellitus	8.47e-05	0.000564	CcSEcCtD
Atomoxetine—Muscle spasms—Ramipril—type 2 diabetes mellitus	8.46e-05	0.000564	CcSEcCtD
Atomoxetine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	8.44e-05	0.000562	CcSEcCtD
Atomoxetine—Somnolence—Metformin—type 2 diabetes mellitus	8.39e-05	0.000559	CcSEcCtD
Atomoxetine—Propafenone—CYP1A2—type 2 diabetes mellitus	8.38e-05	0.0238	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRA2A—type 2 diabetes mellitus	8.38e-05	0.0238	CrCbGaD
Atomoxetine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	8.37e-05	0.000558	CcSEcCtD
Atomoxetine—Infection—Losartan—type 2 diabetes mellitus	8.32e-05	0.000554	CcSEcCtD
Atomoxetine—Dyspepsia—Metformin—type 2 diabetes mellitus	8.3e-05	0.000553	CcSEcCtD
Atomoxetine—Tremor—Ramipril—type 2 diabetes mellitus	8.25e-05	0.000549	CcSEcCtD
Atomoxetine—Shock—Losartan—type 2 diabetes mellitus	8.24e-05	0.000549	CcSEcCtD
Atomoxetine—Urticaria—Valsartan—type 2 diabetes mellitus	8.23e-05	0.000548	CcSEcCtD
Atomoxetine—Nervous system disorder—Losartan—type 2 diabetes mellitus	8.22e-05	0.000547	CcSEcCtD
Atomoxetine—Decreased appetite—Metformin—type 2 diabetes mellitus	8.2e-05	0.000546	CcSEcCtD
Atomoxetine—Abdominal pain—Valsartan—type 2 diabetes mellitus	8.19e-05	0.000545	CcSEcCtD
Atomoxetine—Tachycardia—Losartan—type 2 diabetes mellitus	8.18e-05	0.000545	CcSEcCtD
Atomoxetine—Nausea—Bromocriptine—type 2 diabetes mellitus	8.16e-05	0.000543	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	8.14e-05	0.000542	CcSEcCtD
Atomoxetine—Fatigue—Metformin—type 2 diabetes mellitus	8.13e-05	0.000542	CcSEcCtD
Atomoxetine—Urticaria—Orlistat—type 2 diabetes mellitus	8.13e-05	0.000542	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	8.11e-05	0.00054	CcSEcCtD
Atomoxetine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	8.1e-05	0.000539	CcSEcCtD
Atomoxetine—Body temperature increased—Orlistat—type 2 diabetes mellitus	8.09e-05	0.000539	CcSEcCtD
Atomoxetine—Abdominal pain—Orlistat—type 2 diabetes mellitus	8.09e-05	0.000539	CcSEcCtD
Atomoxetine—Asthenia—Gliclazide—type 2 diabetes mellitus	8.09e-05	0.000539	CcSEcCtD
Atomoxetine—Agitation—Ramipril—type 2 diabetes mellitus	8.09e-05	0.000539	CcSEcCtD
Atomoxetine—Constipation—Metformin—type 2 diabetes mellitus	8.07e-05	0.000537	CcSEcCtD
Atomoxetine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	7.99e-05	0.000532	CcSEcCtD
Atomoxetine—Anorexia—Losartan—type 2 diabetes mellitus	7.99e-05	0.000532	CcSEcCtD
Atomoxetine—Vomiting—Glyburide—type 2 diabetes mellitus	7.98e-05	0.000532	CcSEcCtD
Atomoxetine—Pruritus—Gliclazide—type 2 diabetes mellitus	7.98e-05	0.000531	CcSEcCtD
Atomoxetine—Rash—Glyburide—type 2 diabetes mellitus	7.92e-05	0.000527	CcSEcCtD
Atomoxetine—Somnolence—Irbesartan—type 2 diabetes mellitus	7.91e-05	0.000527	CcSEcCtD
Atomoxetine—Dermatitis—Glyburide—type 2 diabetes mellitus	7.91e-05	0.000527	CcSEcCtD
Atomoxetine—Vertigo—Ramipril—type 2 diabetes mellitus	7.91e-05	0.000527	CcSEcCtD
Atomoxetine—Syncope—Ramipril—type 2 diabetes mellitus	7.89e-05	0.000526	CcSEcCtD
Atomoxetine—Headache—Glyburide—type 2 diabetes mellitus	7.87e-05	0.000524	CcSEcCtD
Atomoxetine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	7.84e-05	0.000522	CcSEcCtD
Atomoxetine—Palpitations—Ramipril—type 2 diabetes mellitus	7.78e-05	0.000518	CcSEcCtD
Atomoxetine—Feeling abnormal—Metformin—type 2 diabetes mellitus	7.77e-05	0.000518	CcSEcCtD
Atomoxetine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	7.74e-05	0.000515	CcSEcCtD
Atomoxetine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	7.74e-05	0.000515	CcSEcCtD
Atomoxetine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	7.71e-05	0.000514	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	7.71e-05	0.000514	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	7.69e-05	0.000512	CcSEcCtD
Atomoxetine—Cough—Ramipril—type 2 diabetes mellitus	7.68e-05	0.000512	CcSEcCtD
Atomoxetine—Fatigue—Irbesartan—type 2 diabetes mellitus	7.68e-05	0.000511	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	7.63e-05	0.000508	CcSEcCtD
Atomoxetine—Convulsion—Ramipril—type 2 diabetes mellitus	7.63e-05	0.000508	CcSEcCtD
Atomoxetine—Pain—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.000507	CcSEcCtD
Atomoxetine—Constipation—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.000507	CcSEcCtD
Atomoxetine—Insomnia—Losartan—type 2 diabetes mellitus	7.58e-05	0.000505	CcSEcCtD
Atomoxetine—Paraesthesia—Losartan—type 2 diabetes mellitus	7.52e-05	0.000501	CcSEcCtD
Atomoxetine—Urticaria—Metformin—type 2 diabetes mellitus	7.49e-05	0.000499	CcSEcCtD
Atomoxetine—Chest pain—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000499	CcSEcCtD
Atomoxetine—Myalgia—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000499	CcSEcCtD
Atomoxetine—Arthralgia—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000499	CcSEcCtD
Atomoxetine—Anxiety—Ramipril—type 2 diabetes mellitus	7.47e-05	0.000497	CcSEcCtD
Atomoxetine—Nausea—Glyburide—type 2 diabetes mellitus	7.46e-05	0.000497	CcSEcCtD
Atomoxetine—Abdominal pain—Metformin—type 2 diabetes mellitus	7.46e-05	0.000497	CcSEcCtD
Atomoxetine—Dizziness—Gliclazide—type 2 diabetes mellitus	7.46e-05	0.000497	CcSEcCtD
Atomoxetine—Somnolence—Losartan—type 2 diabetes mellitus	7.45e-05	0.000496	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	7.44e-05	0.000496	CcSEcCtD
Atomoxetine—Asthenia—Valsartan—type 2 diabetes mellitus	7.43e-05	0.000495	CcSEcCtD
Atomoxetine—Dyspepsia—Losartan—type 2 diabetes mellitus	7.37e-05	0.000491	CcSEcCtD
Atomoxetine—Asthenia—Orlistat—type 2 diabetes mellitus	7.34e-05	0.000489	CcSEcCtD
Atomoxetine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	7.34e-05	0.000489	CcSEcCtD
Atomoxetine—Pruritus—Valsartan—type 2 diabetes mellitus	7.33e-05	0.000488	CcSEcCtD
Atomoxetine—Dry mouth—Ramipril—type 2 diabetes mellitus	7.33e-05	0.000488	CcSEcCtD
Atomoxetine—Decreased appetite—Losartan—type 2 diabetes mellitus	7.28e-05	0.000485	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	7.28e-05	0.000485	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS2—type 2 diabetes mellitus	7.27e-05	0.0206	CrCbGaD
Atomoxetine—Pruritus—Orlistat—type 2 diabetes mellitus	7.24e-05	0.000482	CcSEcCtD
Atomoxetine—Fatigue—Losartan—type 2 diabetes mellitus	7.22e-05	0.000481	CcSEcCtD
Atomoxetine—Vomiting—Gliclazide—type 2 diabetes mellitus	7.17e-05	0.000478	CcSEcCtD
Atomoxetine—Constipation—Losartan—type 2 diabetes mellitus	7.16e-05	0.000477	CcSEcCtD
Atomoxetine—Pain—Losartan—type 2 diabetes mellitus	7.16e-05	0.000477	CcSEcCtD
Atomoxetine—Rash—Gliclazide—type 2 diabetes mellitus	7.11e-05	0.000474	CcSEcCtD
Atomoxetine—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.1e-05	0.000473	CcSEcCtD
Atomoxetine—Diarrhoea—Valsartan—type 2 diabetes mellitus	7.09e-05	0.000472	CcSEcCtD
Atomoxetine—Urticaria—Irbesartan—type 2 diabetes mellitus	7.07e-05	0.000471	CcSEcCtD
Atomoxetine—Shock—Ramipril—type 2 diabetes mellitus	7.07e-05	0.000471	CcSEcCtD
Atomoxetine—Headache—Gliclazide—type 2 diabetes mellitus	7.06e-05	0.00047	CcSEcCtD
Atomoxetine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.05e-05	0.000469	CcSEcCtD
Atomoxetine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.04e-05	0.000469	CcSEcCtD
Atomoxetine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.04e-05	0.000469	CcSEcCtD
Atomoxetine—Modafinil—CYP1A2—type 2 diabetes mellitus	7.02e-05	0.0199	CrCbGaD
Atomoxetine—Tachycardia—Ramipril—type 2 diabetes mellitus	7.01e-05	0.000467	CcSEcCtD
Atomoxetine—Diarrhoea—Orlistat—type 2 diabetes mellitus	7e-05	0.000467	CcSEcCtD
Atomoxetine—Nortriptyline—HTR2C—type 2 diabetes mellitus	6.99e-05	0.0198	CrCbGaD
Atomoxetine—Skin disorder—Ramipril—type 2 diabetes mellitus	6.98e-05	0.000465	CcSEcCtD
Atomoxetine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.94e-05	0.000463	CcSEcCtD
Atomoxetine—Feeling abnormal—Losartan—type 2 diabetes mellitus	6.9e-05	0.00046	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	6.85e-05	0.000456	CcSEcCtD
Atomoxetine—Dizziness—Valsartan—type 2 diabetes mellitus	6.85e-05	0.000456	CcSEcCtD
Atomoxetine—Anorexia—Ramipril—type 2 diabetes mellitus	6.85e-05	0.000456	CcSEcCtD
Atomoxetine—Dizziness—Orlistat—type 2 diabetes mellitus	6.77e-05	0.000451	CcSEcCtD
Atomoxetine—Asthenia—Metformin—type 2 diabetes mellitus	6.77e-05	0.000451	CcSEcCtD
Atomoxetine—Nausea—Gliclazide—type 2 diabetes mellitus	6.7e-05	0.000446	CcSEcCtD
Atomoxetine—Pruritus—Metformin—type 2 diabetes mellitus	6.67e-05	0.000445	CcSEcCtD
Atomoxetine—Urticaria—Losartan—type 2 diabetes mellitus	6.66e-05	0.000443	CcSEcCtD
Atomoxetine—Body temperature increased—Losartan—type 2 diabetes mellitus	6.62e-05	0.000441	CcSEcCtD
Atomoxetine—Abdominal pain—Losartan—type 2 diabetes mellitus	6.62e-05	0.000441	CcSEcCtD
Atomoxetine—Vomiting—Valsartan—type 2 diabetes mellitus	6.59e-05	0.000439	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	6.55e-05	0.000436	CcSEcCtD
Atomoxetine—Rash—Valsartan—type 2 diabetes mellitus	6.53e-05	0.000435	CcSEcCtD
Atomoxetine—Dermatitis—Valsartan—type 2 diabetes mellitus	6.53e-05	0.000435	CcSEcCtD
Atomoxetine—Tolterodine—CYP3A4—type 2 diabetes mellitus	6.52e-05	0.0185	CrCbGaD
Atomoxetine—Vomiting—Orlistat—type 2 diabetes mellitus	6.51e-05	0.000434	CcSEcCtD
Atomoxetine—Insomnia—Ramipril—type 2 diabetes mellitus	6.5e-05	0.000433	CcSEcCtD
Atomoxetine—Headache—Valsartan—type 2 diabetes mellitus	6.49e-05	0.000432	CcSEcCtD
Atomoxetine—Fenoprofen—ALB—type 2 diabetes mellitus	6.47e-05	0.0184	CrCbGaD
Atomoxetine—Diarrhoea—Metformin—type 2 diabetes mellitus	6.45e-05	0.00043	CcSEcCtD
Atomoxetine—Rash—Orlistat—type 2 diabetes mellitus	6.45e-05	0.00043	CcSEcCtD
Atomoxetine—Paraesthesia—Ramipril—type 2 diabetes mellitus	6.45e-05	0.00043	CcSEcCtD
Atomoxetine—Dermatitis—Orlistat—type 2 diabetes mellitus	6.45e-05	0.00043	CcSEcCtD
Atomoxetine—Headache—Orlistat—type 2 diabetes mellitus	6.41e-05	0.000427	CcSEcCtD
Atomoxetine—Phenprocoumon—CYP3A4—type 2 diabetes mellitus	6.4e-05	0.0182	CrCbGaD
Atomoxetine—Asthenia—Irbesartan—type 2 diabetes mellitus	6.39e-05	0.000425	CcSEcCtD
Atomoxetine—Somnolence—Ramipril—type 2 diabetes mellitus	6.39e-05	0.000425	CcSEcCtD
Atomoxetine—Dyspepsia—Ramipril—type 2 diabetes mellitus	6.32e-05	0.000421	CcSEcCtD
Atomoxetine—Pruritus—Irbesartan—type 2 diabetes mellitus	6.3e-05	0.00042	CcSEcCtD
Atomoxetine—Decreased appetite—Ramipril—type 2 diabetes mellitus	6.24e-05	0.000416	CcSEcCtD
Atomoxetine—Dizziness—Metformin—type 2 diabetes mellitus	6.24e-05	0.000416	CcSEcCtD
Atomoxetine—Fluoxetine—CYP3A4—type 2 diabetes mellitus	6.22e-05	0.0177	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	6.2e-05	0.000413	CcSEcCtD
Atomoxetine—Fatigue—Ramipril—type 2 diabetes mellitus	6.19e-05	0.000413	CcSEcCtD
Atomoxetine—Nausea—Valsartan—type 2 diabetes mellitus	6.15e-05	0.00041	CcSEcCtD
Atomoxetine—Constipation—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000409	CcSEcCtD
Atomoxetine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.09e-05	0.000406	CcSEcCtD
Atomoxetine—Nausea—Orlistat—type 2 diabetes mellitus	6.08e-05	0.000405	CcSEcCtD
Atomoxetine—Asthenia—Losartan—type 2 diabetes mellitus	6.01e-05	0.0004	CcSEcCtD
Atomoxetine—Vomiting—Metformin—type 2 diabetes mellitus	6e-05	0.0004	CcSEcCtD
Atomoxetine—Rash—Metformin—type 2 diabetes mellitus	5.95e-05	0.000396	CcSEcCtD
Atomoxetine—Dermatitis—Metformin—type 2 diabetes mellitus	5.94e-05	0.000396	CcSEcCtD
Atomoxetine—Pruritus—Losartan—type 2 diabetes mellitus	5.93e-05	0.000395	CcSEcCtD
Atomoxetine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	5.92e-05	0.000394	CcSEcCtD
Atomoxetine—Headache—Metformin—type 2 diabetes mellitus	5.91e-05	0.000394	CcSEcCtD
Atomoxetine—Dizziness—Irbesartan—type 2 diabetes mellitus	5.89e-05	0.000392	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	5.87e-05	0.000391	CcSEcCtD
Atomoxetine—Desipramine—HTR2C—type 2 diabetes mellitus	5.76e-05	0.0163	CrCbGaD
Atomoxetine—Propranolol—CYP1A2—type 2 diabetes mellitus	5.74e-05	0.0163	CrCbGaD
Atomoxetine—Diarrhoea—Losartan—type 2 diabetes mellitus	5.73e-05	0.000382	CcSEcCtD
Atomoxetine—Urticaria—Ramipril—type 2 diabetes mellitus	5.71e-05	0.00038	CcSEcCtD
Atomoxetine—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.68e-05	0.000378	CcSEcCtD
Atomoxetine—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.68e-05	0.000378	CcSEcCtD
Atomoxetine—Warfarin—CYP3A4—type 2 diabetes mellitus	5.68e-05	0.0161	CrCbGaD
Atomoxetine—Vomiting—Irbesartan—type 2 diabetes mellitus	5.66e-05	0.000377	CcSEcCtD
Atomoxetine—Rash—Irbesartan—type 2 diabetes mellitus	5.61e-05	0.000374	CcSEcCtD
Atomoxetine—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.61e-05	0.000374	CcSEcCtD
Atomoxetine—Nausea—Metformin—type 2 diabetes mellitus	5.6e-05	0.000373	CcSEcCtD
Atomoxetine—Phenprocoumon—ALB—type 2 diabetes mellitus	5.58e-05	0.0158	CrCbGaD
Atomoxetine—Headache—Irbesartan—type 2 diabetes mellitus	5.58e-05	0.000371	CcSEcCtD
Atomoxetine—Propafenone—CYP3A4—type 2 diabetes mellitus	5.55e-05	0.0157	CrCbGaD
Atomoxetine—Nortriptyline—CYP2E1—type 2 diabetes mellitus	5.55e-05	0.0157	CrCbGaD
Atomoxetine—Dizziness—Losartan—type 2 diabetes mellitus	5.54e-05	0.000369	CcSEcCtD
Atomoxetine—Fluoxetine—ALB—type 2 diabetes mellitus	5.43e-05	0.0154	CrCbGaD
Atomoxetine—Vomiting—Losartan—type 2 diabetes mellitus	5.33e-05	0.000355	CcSEcCtD
Atomoxetine—Nausea—Irbesartan—type 2 diabetes mellitus	5.29e-05	0.000352	CcSEcCtD
Atomoxetine—Rash—Losartan—type 2 diabetes mellitus	5.28e-05	0.000352	CcSEcCtD
Atomoxetine—Dermatitis—Losartan—type 2 diabetes mellitus	5.28e-05	0.000352	CcSEcCtD
Atomoxetine—Nortriptyline—CYP1A2—type 2 diabetes mellitus	5.28e-05	0.015	CrCbGaD
Atomoxetine—Headache—Losartan—type 2 diabetes mellitus	5.25e-05	0.00035	CcSEcCtD
Atomoxetine—Asthenia—Ramipril—type 2 diabetes mellitus	5.15e-05	0.000343	CcSEcCtD
Atomoxetine—Pruritus—Ramipril—type 2 diabetes mellitus	5.08e-05	0.000339	CcSEcCtD
Atomoxetine—Nausea—Losartan—type 2 diabetes mellitus	4.98e-05	0.000331	CcSEcCtD
Atomoxetine—Warfarin—ALB—type 2 diabetes mellitus	4.95e-05	0.014	CrCbGaD
Atomoxetine—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.92e-05	0.000327	CcSEcCtD
Atomoxetine—Diphenhydramine—CYP1A2—type 2 diabetes mellitus	4.88e-05	0.0138	CrCbGaD
Atomoxetine—Orphenadrine—CYP2E1—type 2 diabetes mellitus	4.85e-05	0.0138	CrCbGaD
Atomoxetine—Dizziness—Ramipril—type 2 diabetes mellitus	4.75e-05	0.000316	CcSEcCtD
Atomoxetine—Methadone—CYP1A2—type 2 diabetes mellitus	4.71e-05	0.0134	CrCbGaD
Atomoxetine—Modafinil—CYP3A4—type 2 diabetes mellitus	4.65e-05	0.0132	CrCbGaD
Atomoxetine—Vomiting—Ramipril—type 2 diabetes mellitus	4.57e-05	0.000304	CcSEcCtD
Atomoxetine—Desipramine—CYP2E1—type 2 diabetes mellitus	4.57e-05	0.013	CrCbGaD
Atomoxetine—Rash—Ramipril—type 2 diabetes mellitus	4.53e-05	0.000302	CcSEcCtD
Atomoxetine—Dermatitis—Ramipril—type 2 diabetes mellitus	4.53e-05	0.000301	CcSEcCtD
Atomoxetine—Headache—Ramipril—type 2 diabetes mellitus	4.5e-05	0.0003	CcSEcCtD
Atomoxetine—Desipramine—CYP1A2—type 2 diabetes mellitus	4.34e-05	0.0123	CrCbGaD
Atomoxetine—Ketoprofen—PTGS2—type 2 diabetes mellitus	4.29e-05	0.0122	CrCbGaD
Atomoxetine—Nausea—Ramipril—type 2 diabetes mellitus	4.27e-05	0.000284	CcSEcCtD
Atomoxetine—Benzphetamine—CYP3A4—type 2 diabetes mellitus	4.03e-05	0.0114	CrCbGaD
Atomoxetine—Phenoxybenzamine—CYP3A4—type 2 diabetes mellitus	3.85e-05	0.0109	CrCbGaD
Atomoxetine—Ketoprofen—ALB—type 2 diabetes mellitus	3.82e-05	0.0108	CrCbGaD
Atomoxetine—Propranolol—CYP3A4—type 2 diabetes mellitus	3.8e-05	0.0108	CrCbGaD
Atomoxetine—Nortriptyline—CYP3A4—type 2 diabetes mellitus	3.49e-05	0.00991	CrCbGaD
Atomoxetine—Methadone—CYP3A4—type 2 diabetes mellitus	3.12e-05	0.00885	CrCbGaD
Atomoxetine—Orphenadrine—CYP3A4—type 2 diabetes mellitus	3.05e-05	0.00867	CrCbGaD
Atomoxetine—Nortriptyline—ALB—type 2 diabetes mellitus	3.05e-05	0.00865	CrCbGaD
Atomoxetine—Desipramine—CYP3A4—type 2 diabetes mellitus	2.88e-05	0.00816	CrCbGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.31e-06	5.09e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADRA2A—type 2 diabetes mellitus	4.31e-06	5.09e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.31e-06	5.08e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.3e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.29e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.29e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.28e-06	5.05e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.27e-06	5.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	4.25e-06	5.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.24e-06	5.01e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	4.23e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.21e-06	4.97e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.2e-06	4.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOB—type 2 diabetes mellitus	4.19e-06	4.94e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.19e-06	4.94e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.17e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	4.16e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	4.16e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	4.16e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—C3—type 2 diabetes mellitus	4.14e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2E1—type 2 diabetes mellitus	4.14e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.12e-06	4.86e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.11e-06	4.85e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A1—type 2 diabetes mellitus	4.09e-06	4.83e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A2—type 2 diabetes mellitus	4.09e-06	4.83e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	4.09e-06	4.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.08e-06	4.82e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	4.05e-06	4.78e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LPL—type 2 diabetes mellitus	4e-06	4.72e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.99e-06	4.72e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP3A4—type 2 diabetes mellitus	3.99e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	3.97e-06	4.69e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	3.96e-06	4.68e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	3.96e-06	4.67e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.95e-06	4.67e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.94e-06	4.65e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGT—type 2 diabetes mellitus	3.94e-06	4.65e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GCG—type 2 diabetes mellitus	3.93e-06	4.63e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A4—type 2 diabetes mellitus	3.93e-06	4.63e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.92e-06	4.63e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.92e-06	4.63e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.91e-06	4.62e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.89e-06	4.6e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.89e-06	4.6e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.87e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—type 2 diabetes mellitus	3.86e-06	4.55e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—type 2 diabetes mellitus	3.86e-06	4.55e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.82e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.82e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.82e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.82e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.81e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.81e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.81e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	3.81e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	3.77e-06	4.45e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	3.77e-06	4.45e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.75e-06	4.43e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RELA—type 2 diabetes mellitus	3.69e-06	4.36e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.68e-06	4.35e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	3.67e-06	4.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RELA—type 2 diabetes mellitus	3.67e-06	4.33e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.66e-06	4.32e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.64e-06	4.29e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	3.61e-06	4.26e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	3.61e-06	4.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—C3—type 2 diabetes mellitus	3.6e-06	4.25e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RELA—type 2 diabetes mellitus	3.59e-06	4.24e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.44e-06	4.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.43e-06	4.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.42e-06	4.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGT—type 2 diabetes mellitus	3.42e-06	4.04e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	3.41e-06	4.02e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	3.38e-06	3.99e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.38e-06	3.99e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	3.37e-06	3.98e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.36e-06	3.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.36e-06	3.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—type 2 diabetes mellitus	3.35e-06	3.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—type 2 diabetes mellitus	3.35e-06	3.95e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.34e-06	3.94e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.33e-06	3.93e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	3.32e-06	3.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.31e-06	3.91e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.31e-06	3.91e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.31e-06	3.9e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—type 2 diabetes mellitus	3.3e-06	3.89e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.28e-06	3.88e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.27e-06	3.86e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.24e-06	3.83e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.24e-06	3.82e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	3.23e-06	3.81e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.22e-06	3.8e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.19e-06	3.76e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.19e-06	3.76e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	3.18e-06	3.75e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.17e-06	3.74e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.16e-06	3.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.15e-06	3.72e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	3.14e-06	3.71e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.12e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.12e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	3.12e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	3.12e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	3.11e-06	3.67e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.11e-06	3.67e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	3.1e-06	3.66e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.09e-06	3.65e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	3.08e-06	3.64e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.06e-06	3.61e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	3.06e-06	3.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	3.05e-06	3.61e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.05e-06	3.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	3.04e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	3.04e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	3.04e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.03e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.03e-06	3.57e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.03e-06	3.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	3.02e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	3.02e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	3.01e-06	3.55e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.99e-06	3.53e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.97e-06	3.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.97e-06	3.5e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.96e-06	3.5e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.93e-06	3.46e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	2.93e-06	3.46e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SRC—type 2 diabetes mellitus	2.9e-06	3.43e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	2.89e-06	3.41e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.89e-06	3.41e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.89e-06	3.41e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.89e-06	3.41e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SRC—type 2 diabetes mellitus	2.88e-06	3.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	2.86e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.83e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.83e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SRC—type 2 diabetes mellitus	2.82e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.82e-06	3.32e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.81e-06	3.31e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.77e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	2.77e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.77e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.77e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.76e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.75e-06	3.25e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.75e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.72e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.72e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.72e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	2.72e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	2.72e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.69e-06	3.18e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.67e-06	3.16e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2.66e-06	3.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.65e-06	3.13e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	2.64e-06	3.11e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.63e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.59e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.59e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	2.59e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	2.58e-06	3.05e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.58e-06	3.04e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	2.55e-06	3.01e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	2.55e-06	3.01e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.54e-06	3e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.52e-06	2.98e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.52e-06	2.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.51e-06	2.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.51e-06	2.96e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	2.5e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.49e-06	2.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.48e-06	2.92e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.47e-06	2.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.46e-06	2.91e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.46e-06	2.91e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.45e-06	2.9e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.44e-06	2.88e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	2.42e-06	2.86e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.38e-06	2.81e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.37e-06	2.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.36e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.36e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.36e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.35e-06	2.77e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.32e-06	2.74e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.29e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	2.25e-06	2.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.25e-06	2.65e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	2.21e-06	2.6e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.15e-06	2.54e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	2.14e-06	2.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.13e-06	2.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.12e-06	2.5e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.08e-06	2.46e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	2.07e-06	2.44e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	2.03e-06	2.4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.03e-06	2.4e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	2.03e-06	2.4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	2.03e-06	2.39e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	2.02e-06	2.39e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.01e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	2e-06	2.36e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.99e-06	2.35e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	1.96e-06	2.31e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.95e-06	2.31e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	1.94e-06	2.29e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.94e-06	2.29e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	1.93e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	1.93e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.91e-06	2.26e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.9e-06	2.24e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.89e-06	2.23e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.87e-06	2.21e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.86e-06	2.2e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.86e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.85e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.81e-06	2.14e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.81e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.81e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.8e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.79e-06	2.11e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.78e-06	2.1e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.78e-06	2.1e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	1.77e-06	2.09e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.76e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.75e-06	2.07e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.74e-06	2.05e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.67e-06	1.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.66e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.64e-06	1.93e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.63e-06	1.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.63e-06	1.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.58e-06	1.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.56e-06	1.84e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.55e-06	1.83e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.53e-06	1.81e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	1.44e-06	1.7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.35e-06	1.6e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.33e-06	1.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.33e-06	1.57e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.25e-06	1.48e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.22e-06	1.44e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.16e-06	1.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.16e-06	1.37e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.15e-06	1.36e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.06e-06	1.26e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	8.89e-07	1.05e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	8.18e-07	9.66e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	5.35e-07	6.31e-06	CbGpPWpGaD
